Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiratricol withdrawal study in males with MCT8 deficiency
NL-OMON53686Phase 3Recruiting
- Sponsor
- Egetis Therapeutics
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiratricol in Allan-Herndon-Dudley syndrome (AHDS), sponsored by Egetis Therapeutics. Primary endpoint: Proportion meeting rescue criterion. Started Jul 2023; status: recruiting.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on NL-OMON53686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53686.